U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07835971) titled 'A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential Hypertension' on Sept. 17.
Brief Summary: The purpose of this study is to evaluate the effect of GW906 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of GW906.
Study Start Date: Dec. 24, 2025
Study Type: INTERVENTIONAL
Condition:
Hypertension
Intervention:
DRUG: GW906
Subcutaneous injection
DRUG: Placebo
Subcutaneous injection
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
Published by HT Digital Content Services with permission from Health ...